Evidence map›Paper›PMID 36798265›Full record

ArticlebioRxiv : the preprint server for biology2023

STAT3 protects HSCs from intrinsic interferon signaling and loss of long-term blood-forming activity.

Bhakti Patel, Yifan Zhou, Rachel L Babcock, Feiyang Ma, Malgorzata A Zal, Dhiraj Kumar, Yusra B Medik, Laura M Kahn, Josué E Pineda, Elizabeth M Park and 7 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Bhakti PatelDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yifan ZhouDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rachel L BabcockDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Feiyang MaMolecular Biology Institute, University of California, Los Angeles, Los Angeles, CA, USA.
Malgorzata A ZalDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dhiraj KumarHerbert Irving Cancer Center and Department of Genetics and Development, Columbia University, New York, NY, USA.
Yusra B MedikDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Laura M KahnDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Josué E PinedaDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Elizabeth M ParkDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ximing TangDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Maria Gabriela RasoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tomasz ZalDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Karen Clise-DwyerDepartment of Stem Cell Transplantation and Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Filippo G GiancottiHerbert Irving Cancer Center and Department of Genetics and Development, Columbia University, New York, NY, USA.
Simona CollaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Stephanie S WatowichDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · USColumbia University · USUniversity of California, Los Angeles · US

Funding

Mechanisms governing metastatic dormancy and reactivationR35CA197566 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GIANCOTTI, FILIPPO G · 2016 to 2022
$6.7M
Defining Protective Responses in Hematopoietic Cells Mediated by STAT3 Anti-Inflammatory ActivityR01AI133822 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WATOWICH, STEPHANIE S · 2018 to 2022
$2.1M
Super-Resolution OMX MicroscropeS10RR029552 · NCRR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ZAL, TOMASZ · 2011 to 2011
$1.0M
NovaSeq6000S10OD024977 · OD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HUFF, VICKI · 2018 to 2018
$995k
Regulation and function of nonlymphoid organ CD103+ dendritic cellsR56AI109294 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WATOWICH, STEPHANIE S · 2021 to 2021
$481k
NCI NIH HHS R35 CA197566NCRR NIH HHS S10 RR029552NIAID NIH HHS R01 AI133822NIAID NIH HHS R56 AI109294NIH HHS S10 OD024977
6 · The paper itself

Abstract

STAT3 function in hematopoietic stem and progenitor cells (HSPCs) has been difficult to discern as

Indexed as

cell cycleDNA damagehematopoietic stem cellIFN signalingSTAT3

Identifiers

PMID36798265
PMCPMC9934695
OpenAlexW4320182994

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.